Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048063 | 0.90 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL3298165 | 0.87 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5060097 | 0.87 | MAPK14 (0.85) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL13296939 | 0.85 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL2084459 | 0.84 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL2083175 | 0.83 | MAPK14 (0.77) | MAPK14MAPK11ABL1RAF1BRAF | |
| SCHEMBL13315346 | 0.81 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3296100 | 0.81 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL3297354 | 0.81 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL4263729 | 0.80 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MAPK14 80/4885MAPK13 183/4885MAPK12 118/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAPK14 29/4885MAPK13 41/4885MAPK12 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.